Updated Apr 12, 2019

Grand Challenges Explorations  FUNDING INITIATIVE

http://gcgh.grandchallenges.org/announcement/grand-challenges-explorations-announced

About Grand Challenges Explorations

The Bill & Melinda Gates Foundation announced that it was committing $100 million over five years to create a new fast-track grants initiative to support innovative, early-stage global health research. The new program, called Grand Challenges Explorations, was an expansion of the Gates Foundation's commitment to the Grand Challenges in Global Health. The program's goal is to engage more of the world's innovators and to do so more quickly. Initial grants are for $100,000; successful projects can be awarded follow-on grants of up to $1 million.
READ MORE
$255,589,172
To Date
?
1,359
Funded Innovations
1,514
Funded Deals
?
?
1,000,100
Lives Impacted
?
Where we work
Africa
Asia and Pacific
Europe and Eurasia
Latin America / Caribbean
North America
Middle East and North Africa
Focus Areas
Health

Funding History

WINNER
DEC 2018
A Novel Platform for Screening Non-Hormonal ContraceptivesA Novel Platform for Screening Non-Hormonal Contraceptives
  • $742,367VERIFIED
    1. TITLEA High-Throughput Platform for Screening Non-Hormonal Contraceptives
    2. TYPEGrant
    3. FOCUS AREASMaternal Newborn and Child Health
    4. ORGANIZATIONBill & Melinda Gates FoundationBill & Melinda Gates Foundation as part of Grand Challenges ExplorationsGrand Challenges Explorations
    WINNER
    NOV 2018
    In Vitro Ovulation Microfluidic Assay Development and ValidationIn Vitro Ovulation Microfluidic Assay Development and Validation
  • $1,000,000VERIFIED
    1. TITLEHigh-throughput Ovulation Screening Assay for Contraception Discovery Applications
    2. TYPEGrant
    3. FOCUS AREASMaternal Newborn and Child Health
    4. ORGANIZATIONBill & Melinda Gates FoundationBill & Melinda Gates Foundation as part of Grand Challenges ExplorationsGrand Challenges Explorations
    WINNER
    NOV 2018
    Reversible Contraceptives that Block Primordial FolliclesReversible Contraceptives that Block Primordial Follicles
  • $855,450VERIFIED
    1. TITLEA Pipeline to Screen and Validate MISR2 Agonists as Contraceptives that Inhibit Primordial Follicles
    2. TYPEGrant
    3. FOCUS AREASMaternal Newborn and Child Health
    4. ORGANIZATIONBill & Melinda Gates FoundationBill & Melinda Gates Foundation as part of Grand Challenges ExplorationsGrand Challenges Explorations
    SEE 30 MORE of 1514